HRTS
Heart & Health ETF

Invest in Healthcare Companies Fighting Chronic Disease.

Share Price:

$34.78

March 10, 2026

Why Invest in HRTS?

High Growth Potential

Healthcare is a critical sector of the U.S. economy, and its share has been rising for generations—projected to approach one-fifth of GDP by 2030.

MedPac, 2024

Breakthrough Innovations

Global weight-loss therapy sales are projected to reach $100bn annually by the end of the decade, underscoring the scale of one major breakthrough—and the potential for more to follow.

McKinsey, 2026

Investment Expertise

HRTS is managed by a Penn-trained physician and veteran investor with more than two decades of healthcare investing experience.

Fund Overview

Fund Details

As of March 10, 2026

Ticker

HRTS

CUSIP

87975E883

Fund Inception Date

11/20/23

AuM ($)

$53,201,352

Net Expense Ratio*

0.75%

Gross Expense Ratio

0.99%

# of Holdings

Shares Outstanding

1,530,000

Portfolio Manager

David K. Song, MD, PhD, CFA

Primary Exchange

Nasdaq

*Contractual expense cap for net expense ratio of 0.75% is in effect through 06/28/2027.

Fund Summary

The Tema Heart & Health ETF (HRTS) invests in companies advancing prevention and treatment across chronic conditions, including heart disease, diabetes, and obesity.

HRTS Overview

Summary Prospectus

Introducing HRTS

Portfolio Breakdown

Top 10 holdings

As of March 10, 2026

Company

% of Nav

ELI LILLY & CO

9.91%

ROCHE HOLDING AG

5.10%

JOHNSON & JOHNSON

4.71%

ASTRAZENECA PLC

4.70%

MERCK & CO INC

4.16%

THERMO FISHER SCIENTIFIC INC

3.98%

UNITEDHEALTH GROUP INC

3.85%

GILEAD SCIENCES INC

3.75%

VERTEX PHARMACEUTICALS INC

3.51%

NOVARTIS AG

3.47%

Download Holdings

Country Breakdown

United States

74.50%

Switzerland

8.57%

United Kingdom

4.70%

Denmark

3.98%

Others

8.25%

Industry Breakdown

Health Care

98.97%

Cash & Cash Equivalents

0.70%

Performance
Distributions
Premium / Discount

Prices & Performance

As of

Feb 28, 2026

HRTS

3 months

1 Year

3 Years

5 Years

Since inception

NAV

2.02% 15.78%

18.80% 23.64%

16.12% 16.18%

Market Price

1.94% 15.58%

18.84% 23.89%

16.06% 16.15%

Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Returns for periods of less than one year are not annualized.

The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.

Distributions

Record Date

Ex-Date

Payable Date

Total Distribution

Income

Dec 11, 2024

Dec 12, 2024

$0.46931283

$0.14290283

Dec 10, 2025

Dec 11, 2025

$0.47290596

0.01 0.03 0.03 -0.1 0.11 0.09 0.01 0.19 0.04 -0.38 -0.25 -0.08 -0.37 -0.39 0.12 -0.31 0.09 0 -0.17 -0.22 0.13 -0.11 -0.5

Premium/Discount

Сhart Table

Days Traded at Nav

Days Traded at Premium

Days Traded at Discount

2023/Q4

2024/Q1

2024/Q2

2024/Q3

2024/Q4

2025/Q1

2025/Q2

2025/Q3

2025/Q4

HRTS NAV / Market Price

NAV$34.77

NAV change (1D)$0.03

Median Bid/Ask Spread (30 Day)0.28%

Market Price$34.78

Market Price Change (1D)$0.02

Premium/Discount0.01%

As of: March 10, 2026

March-26 February-26 January-26 December-25 November-25 October-25 September-25 August-25 July-25 June-25 May-25 April-25 March-25

How does the Tema HRTS ETF fit in a portfolio?

Investment Style Box

Source: Tema. The investment style Box reveal’s a fund’s investment strategy by showing its investment style and market capitalization based on the fund’s portfolio holdings.

Potential Portfolio

Equity Allocation

3-5%

Equity Satellite

portfolio chart-Jan-12-2024-05-49-21-8745-PM

HRTS ETF

Equity core

Where could a position be funded from?

Could be a more targeted alternative to existing healthcare or biopharma exposure in a portfolio.
Provides a balanced exposure across key technologies and company risk profiles.
Could replace a satellite or a growth-oriented position.

How to buy

*Neither Tema ETFs LLC nor undefined ETF are affiliated with these financial services firms. Their listing should not be viewed as a recommendation or endorsement.

Latest Research & Insights

Stay informed with our latest research, insights, and market analysis to make better investment decisions.

Is Healthcare the Most Mispriced AI Opportunity?

Discover why healthcare, trading at a significant discount to tech and AI stocks, might be the most undervalued AI investment opportunity today.

Read the Full Article

White Paper: Healthcare’s Next Cycle is Taking Shape

An in-depth perspective on the recovery and future growth of the healthcare sector, driven by innovation and AI, as outlined in Dr David Song's latest whitepaper.

Read the Full Article

Why Healthcare is Going Back on Offense in 2026

Discover why healthcare is poised for growth in 2026, driven by policy clarity, AI advancements, and strategic M&A initiatives in pharma, biotech, and medtech.

Read the Full Article

Risk Information

Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com.
Read the prospectus carefully before investing.

On 06/27/2025 the Tema GLP-1, Obesity & Cardiometabolic ETF was renamed Tema Heart & Health ETF. Investing involves risk including possible loss of principal. There is no guarantee the adviser’s investment strategy will be successful.

Industry Concentration Risk: Because the Fund's assets will be concentrated in an industry or group of industries, the Fund is subject to loss due to adverse occurrences that may affect that industry or group of industries.

Biotechnology Industry Risk: The biotechnology industry can be significantly affected by patent considerations, including the termination of patent protections for products, intense competition both domestically and internationally, rapid technological change and obsolescence, government regulation and expensive insurance costs due to the risk of product liability lawsuits. In addition, the biotechnology industry is an emerging growth industry, and therefore biotechnology companies may be thinly capitalized and more volatile than companies with greater capitalizations.

Sector Focus Risk: Obesity and Cardiology companies are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company’s valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The stock prices of Obesity and Cardiology companies have been and will likely continue to be very volatile. The costs associated with developing new drugs can be significant, and the results are unpredictable.

Newly developed drugs may be susceptible to product obsolescence due to intense competition from new products and less costly generic products. Moreover, the process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained. Companies in the medical equipment industry group may be affected by the expiration of patents, litigation based on product liability, industry competition, product obsolescence and regulatory approvals, among other factors.

Investing in foreign and emerging markets involves risks relating to political, economic, or regulatory conditions not associated with investments in U.S. securities and instruments. In addition, the fund is exposed to currency risk.

Because the Funds evaluate ESG factors to assess and exclude certain investments for non-financial reasons, the Funds may forego some market opportunities available to funds that do not use these ESG factors.

Tema ETFs LLC serves as the investment adviser to Tema Heart & Health ETF (the “Fund”), and Tidal Investments LLC serves as a sub adviser to the Fund. The Fund is distributed by Vigilant Distributors, LLC, which is not affiliated with Tema ETFs LLC nor Tidal Investments LLC. Check the background of Vigilant Distributors, LLC on FINRA’s BrokerCheck.

Get in Touch

HRTS Heart & Health ETF

$34.78

Why Invest in HRTS?

High Growth Potential

Breakthrough Innovations

Investment Expertise

Fund Overview

Fund Details

As of March 10, 2026

Fund Summary

Introducing HRTS

Portfolio Breakdown

Top 10 holdings

As of March 10, 2026

Country Breakdown

United States

Switzerland

United Kingdom

Denmark

Others

Industry Breakdown

Health Care

Cash & Cash Equivalents

Prices & Performance

HRTS

3 months

1 Year

3 Years

5 Years

Since inception

Distributions

Record Date

Ex-Date

Payable Date

Total Distribution

Income

Premium/Discount

Days Traded at Nav

Days Traded at Premium

Days Traded at Discount

HRTS NAV / Market Price

How does the Tema HRTS ETF fit in a portfolio?

Investment Style Box

Potential Portfolio

Equity Allocation

3-5%

Equity Satellite

Where could a position be funded from?

Fund Documents

How to buy

Latest Research & Insights

Is Healthcare the Most Mispriced AI Opportunity?

White Paper: Healthcare’s Next Cycle is Taking Shape

Why Healthcare is Going Back on Offense in 2026

Subscribe for Updates

Explore our ETFs

TOLL

CANC

RSHO

VOLT

DSPY

Risk Information

HRTS
Heart & Health ETF